Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience

De Giorgi, U; Demirer, TANER; Wandt, H; Taverna, C; Siegert, W; Bornhauser, M; Kozak, T; Papiani, G; Ballardini, M; Rosti, G

doi:10.1093/annonc/mdi017

Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience

De Giorgi U., Demirer T., Wandt H., Taverna C., Siegert W., Bornhauser M., ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.16, sa.1, ss.146-151, 2005 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 16 Sayı: 1
Basım Tarihi: 2005
Doi Numarası: 10.1093/annonc/mdi017
Dergi Adı: ANNALS OF ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.146-151
Anahtar Kelimeler: EBMT, extragonadal, high-dose chemotherapy, non-seminomatous germ cell tumor, second-line chemotherapy, SALVAGE CHEMOTHERAPY, PROGNOSTIC VARIABLES, CISPLATIN
Ankara Üniversitesi Adresli: Evet

Özet

Background: Results of second-line chemotherapy in patients with extragonadal non-seminomatous germ cell tumor (NSGCT) appear inferior to results in testicular NSGCT. Patients with retroperitoneal NSGCT achieve a comparable long-term survival rate of 30%, but the salvage rates of patients with mediastinal primary are less than 10%. We conducted a retrospective analysis on patients with mediastinal and retroperitoneal NSGCT treated with second-line high-dose chemotherapy (HDCT) registered with the European Group for Blood and Marrow Transplantation (EBMT).